^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MLPH (Melanophilin)

i
Other names: MLPH, Melanophilin, Exophilin-3, Slp Homolog Lacking C2 Domains A, Synaptotagmin-Like Protein 2a, L(1)-3Rk, SLAC2-A, Slac-2a, SlaC2-A, SLAC2A, L1Rk3, Ln
22d
Proteomics-derived biomarker panel facilitates distinguishing primary lung adenocarcinomas with intestinal or mucinous differentiation (PAIM) from lung metastatic colorectal cancer (lmCRC). (PubMed, Mol Cell Proteomics)
Our study depicts PAIM-specific proteomic characteristics and demonstrates the potential utility of new protein biomarkers for the differential diagnosis of PAIM and lmCRC. These findings may contribute to improving the diagnostic accuracy and guide appropriate treatments for these patients.
Journal • Metastases
|
MLPH (Melanophilin) • CDH17 (Cadherin 17) • FABP1 (Fatty Acid Binding Protein 1)
|
CDH1 expression
3ms
Bimetallic bis-Aroyldihydrazone-Isatin Complexes of High O=V(IV) and Low Cu(II) Valent Ions as Effective Biological Reagents for Antimicrobial and Anticancer Assays. (PubMed, Molecules)
Both VOLph and CuLph showed remarkable interactive binding with ctDNA compared to the free ligand HLph, based on K = 16.31, 16.04 and 12.41 × 10 mol dm and ΔGb≠ = 47.11, -46.89, and -44.05 kJ mol for VOLph, CuLph, and HLph, respectively, due to the central metal ion (VO and Cu ions). VOLph (with a higher oxidation state of the V ion and oxo-ligand) exhibited enhanced interaction with the ctDNA molecule compared to CuLph, demonstrating the role and type of the central metal ion within the performed electronegative and electrophilic characters.
Journal
|
MLPH (Melanophilin)
5ms
Chemical Composition and Skin-Whitening Activities of Siegesbeckia glabrescens Makino Flower Absolute in Melanocytes. (PubMed, Plants (Basel))
In addition, SGMFAb reduced the expressions of three melanosome-transport-participating proteins (myosin Va, melanophilin, and Rab27a) in α-MSH-stimulated B16BL6 cells. These results indicate that SGMFAb positively influences skin whitening activities by inhibiting melanogenesis and melanosome-transport-related events in B16BL6 cells, and suggest that SGMFAb is a promising material for developing functional skin whitening agents.
Journal
|
MITF (Melanocyte Inducing Transcription Factor) • MLPH (Melanophilin) • RAB27A (RAB27A, Member RAS Oncogene Family)
6ms
O-GlcNAcylation of melanophilin enhances radiation resistance in glioblastoma via suppressing TRIM21 mediated ubiquitination. (PubMed, Oncogene)
Our data demonstrate that MLPH exerts regulatory functions in GBM radiation resistance by promoting the NF-κB signaling pathway and that O-GlcNAcylation of MLPH both stabilizes and protects it from TRIM21-mediated ubiquitination. These results identify a potential mechanism of GBM radiation resistance and suggest a potential therapeutic strategy for GBM treatment.
Journal
|
MLPH (Melanophilin) • TRIM21 (Tripartite Motif Containing 21)
7ms
Anti-melanogenic effect of exosomes derived from human dermal fibroblasts (BJ-5ta-Ex) in C57BL/6 mice and B16F10 melanoma cells. (PubMed, Pigment Cell Melanoma Res)
In UVB-irradiated mouse ears, BJ-5ta-Ex reduced the number of active melanocytes and melanin granules. These results demonstrate that BJ-5ta-Ex can be useful for the clinical treatment of hyperpigmentation disorders.
Preclinical • Journal
|
TYRP1 (Tyrosinase Related Protein 1) • MITF (Melanocyte Inducing Transcription Factor) • MLPH (Melanophilin) • RAB27A (RAB27A, Member RAS Oncogene Family)
9ms
Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies (ESMO 2023)
These findings are currently being confirmed using Cancer Research Institute iAtlas, a database that contains gene expression for over 1,100 cancer patients across five different tissue types. Specific adjustments may be required to account for differences in gene expression measurements between the training and testing tests.
IO biomarker
|
MVP (Major Vault Protein) • DKC1 (Dyskerin Pseudouridine Synthase 1) • MLPH (Melanophilin)
11ms
LncRNA HOXA11-AS modulates the miR-148b-3p/MLPH axis to promote prostate cancer cell proliferation. (PubMed, Cell Mol Biol (Noisy-le-grand))
MLPH was positively associated with HOXA11-AS and overexpressed it accelerated the progression of prostate cancer. Taken together, HOXA11-AS elevated MLPH expression by sponging miR-148b-3p and accelerated prostate cancer cell proliferation.
Journal
|
CASP3 (Caspase 3) • HOXA11 (Homeobox A11) • MLPH (Melanophilin) • HOXA11-AS (HOXA11 Antisense RNA) • MIR148B (MicroRNA 148b)
|
HOXA11 overexpression
11ms
Indirect CRISPR screening with photoconversion revealed key factors of drug resistance with cell-cell interactions. (PubMed, Commun Biol)
Indirect CRISPR screening was established to isolate the responsible elements of cell-cell interactions. This screening method could reveal unknown mechanisms in all kinds of cell-cell interactions by revealing live phenotype-inducible cells, and it could be a platform for discovering new targets of drugs for conventional chemotherapies.
Journal
|
CXCL12 (C-X-C Motif Chemokine Ligand 12) • MLPH (Melanophilin)
1year
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study. (ASCO 2023)
Abemaciclib not reported due to low numbers (n=16). We confirmed independent prognostic value of CES in first-line setting, suggesting a not statistically significant benefit with ribociclib vs palbociclib in CES-I. >
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FOXA1 (Forkhead Box A1) • MIA (MIA SH3 Domain Containing) • MLPH (Melanophilin)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • CCND1 expression • CCNE1 expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
over1year
Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. (PubMed, J Extracell Vesicles)
We show that reduced Ca -signaling after knockdown of ORAI1 gene also compromises the activity of melanophilin and Synaptotagmin-like protein 2, two proteins, which are important for correct localization of secretory organelles within cancer cells and their transport to sites of exocytosis. Thus, the Ca -channel ORAI1 and Ca -dependent proteins of the secretion pathway emerge as important targets for understanding and manipulating immune checkpoint blockade by PD-L1.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • RAI1 (Retinoic Acid Induced 1) • MLPH (Melanophilin)
|
PD-L1 expression
over1year
Estrogen receptor-negative progesterone receptor-positive breast cancer is a molecularly distinct group characterized by the down-regulation of genes controlled by ESR1 and SUZ12 (SABCS 2022)
ER–/PgR+ BCs display a distinct mRNA expression profile characterized by the down-regulation of genes controlled by ESR1 and SUZ12. The latter as a part of Polycomb Repressive Complex 2 contributes to chromatin silencing, and some previous studies suggested its role in the regulation of steroid hormone receptors expression. Additionally, ER–/PgR+ BCs overexpress FOXC1 which is linked to more aggressive, high-grade, and treatment-resistant breast cancers.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • NOTCH1 (Notch 1) • IRF1 (Interferon Regulatory Factor 1) • SLC44A4 (Solute Carrier Family 44 Member 4) • FOXM1 (Forkhead Box M1) • CDC20 (Cell Division Cycle 20) • FOXC1 (Forkhead Box C1) • MLPH (Melanophilin) • SLC4A4 (Solute carrier family 4 member 4) • E2F1 (E2F transcription factor 1) • SPDEF (SAM Pointed Domain Containing ETS Transcription Factor) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
|
HR positive • ER negative • PGR positive • IRF1 expression • PGR expression • PGR overexpression
|
nCounter® Breast Cancer 360™ Panel
over1year
E2F1 Affects the Therapeutic Response to Neoadjuvant Therapy in Breast Cancer. (PubMed, Dis Markers)
And E2F1 may be involved in the process of drug resistance by regulating the MAPK signaling pathway. These might be useful as sensitive genes for the efficacy evaluation of neoadjuvant chemotherapy in breast cancer.
Journal
|
IL7R (Interleukin 7 Receptor) • FOXA1 (Forkhead Box A1) • HOXA9 (Homeobox A9) • SLC39A6 (Solute Carrier Family 39 Member 6) • MLPH (Melanophilin) • TFF1 (Trefoil Factor 1) • E2F1 (E2F transcription factor 1) • SPDEF (SAM Pointed Domain Containing ETS Transcription Factor)
almost2years
Identification of fusions with potential clinical significance in melanoma. (PubMed, Mod Pathol)
One patient with an AGAP3::BRAF fusion positive melanoma experienced a 30-month long response to trametinib. We show that, detecting fusions, especially in triple wild-type melanomas with TERT promoter mutations, may have a clinically significant impact in patients with advanced disease who have failed front-line immunotherapy.
Journal • IO biomarker
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • CCDC6 (Coiled-Coil Domain Containing 6) • AGK (Acylglycerol Kinase) • CDH3 (Cadherin 3) • MLPH (Melanophilin) • ETV4 (ETS Variant Transcription Factor 4)
|
BRAF mutation • RAS mutation • BRAF fusion • TERT mutation • TERT promoter mutation
|
Mekinist (trametinib)
almost2years
Peripheral benzodiazepine receptor TSPO needs to be reconsidered before using as a drug target for a pigmentary disorder. (PubMed, FASEB J)
These results indicated that Ro5-4864 induces melanogenesis in a TSPO-independent manner, which is inconsistent with previous research. This research is a reminder that we need to be very careful during target validation in drug development.
Journal
|
MLPH (Melanophilin)
2years
Rhamnazin suppresses melanosome transport by promoting the ubiquitin-mediated proteasomal degradation of melanophilin. (PubMed, J Dermatol Sci)
We found that rhamnazin inhibits intracellular transport of melanosomes through proteasomal degradation of MLPH. Our results suggest that topical application of rhamnazin may provide a new approach for treating skin pigmentation disorders.
Preclinical • Journal
|
MLPH (Melanophilin)
2years
Natural Citrus flavanone 5-demethylnobiletin stimulates melanogenesis through the activation of cAMP/CREB pathway in B16F10 cells. (PubMed, Phytomedicine)
The findings suggested that 5-demethylnobiletin may be considered as a potential natural product candidate for patients with pigment disorder.
Journal
|
MITF (Melanocyte Inducing Transcription Factor) • MLPH (Melanophilin)
over2years
H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility. (PubMed, Am J Hum Genet)
HiChIP predicted enhancer elements at the AR and NKX3-1 prostate cancer risk loci, and both were experimentally confirmed to regulate expression of the corresponding genes through CRISPR interference (CRISPRi) perturbation in LNCaP cells. Our results demonstrate that looping data harbor additional information beyond eQTLs and expand the number of PrCa GWAS loci that can be linked to candidate susceptibility genes.
Preclinical • Journal
|
MLPH (Melanophilin) • NKX3-1 (NK3 homeobox 1)
over2years
Overexpression of MLPH in Rectal Cancer Patients Correlates with a Poorer Response to Preoperative Chemoradiotherapy and Reduced Patient Survival. (PubMed, Diagnostics (Basel))
After uni- and multi-variable analysis of five-year survival, MLPH expression was still associated with lower DSS (hazard ratio (HR), 10.110; 95% confidence interval (CI), 2.178-46.920; p = 0.003) and MeFS (HR, 5.621; 95% CI, 1.762-17.931; p = 0.004). In conclusion, identifying MLPH expression could help to predict the response to chemoradiation and survival, and aid in personal therapeutic modification.
Clinical • Journal
|
MLPH (Melanophilin)
|
MLPH overexpression
over2years
Evolutionary selection of alleles in the melanophilin gene that impacts on prostate organ function and cancer risk. (PubMed, Evol Med Public Health)
Variants within the melanophilin (MLPH) gene fell into this category. Depletion of MLPH in prostate organoid cultures, suggested a potential functional mechanism for impacting on cancer risk, as a serendipitous consequence of prior evolutionary benefits to another tissue.
Journal
|
MLPH (Melanophilin)
over2years
Salicylic acid in ginseng root alleviates skin hyperpigmentation disorders by inhibiting melanogenesis and melanosome transport. (PubMed, Eur J Pharmacol)
Furthermore, salicylic acid treatment suppressed expression of transport complex-associated proteins melanophilin and myosin Va in two UVB-treated melanocytic cell lines, suppressed phagocytosis of fluorescent microspheres by UVB-stimulated human keratinocytes (HaCaT), inhibited protease-activated receptor 2 activation by reducing both Ca release and activation of phosphoinositide 3 kinase/AKT and mitogen-activated protein kinases and induced anti-melanogenic effects in zebrafish. Collectively, these results indicate that salicylic acid within ginseng root can inhibit melanocyte melanogenesis and melanin transport, while also suppressing keratinocyte phagocytic function.
Journal
|
TYRP1 (Tyrosinase Related Protein 1) • MITF (Melanocyte Inducing Transcription Factor) • MLPH (Melanophilin)
3years
[VIRTUAL] Understanding the biologic determinants of ribociclib efficacy in breast cancer (ESMO-BC 2021)
 In BC PDXs, B-L biology associates with lower response to ribociclib monotherapy than Luminal or HER2-E. Ribociclib induces a luminal phenotype with high GE of estrogen-regulated genes and low GE of proliferation genes, a biological switch that could explain the better efficacy of ribociclib in the endocrine therapy (ET)-resistant HER2-E subtype observed in clinical trials when combined with ET.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • FOXA1 (Forkhead Box A1) • GRB7 (Growth Factor Receptor Bound Protein 7) • KRT17 (Keratin 17) • CXXC5 (CXXC Finger Protein 5) • KRT14 (Keratin 14) • CDH3 (Cadherin 3) • GPR160 (G Protein-Coupled Receptor 160) • KRT5 (Keratin 5) • MLPH (Melanophilin) • SFRP1 (Secreted frizzled related protein 1)
|
HR positive • HER-2 negative • HER-2 expression • MYC expression • HR positive + HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Kisqali (ribociclib)